Psilocybin Clinical Trials 2023

Psilocybin studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect psilocybin clinical trial in 2023.

Reviewed by Michael Gill, B. Sc.
Image of Centre for Addiction and Mental Health in Toronto, Canada.

Amnestic Mild Cognitive Impairment Participants Receiving Psilocybinfor Mild Cognitive Impairment

60 - 75
All Sexes
Toronto, Canada
The goal of this clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition. 60 participants (30 with aMCI, and 30 sex and age matched healthy volunteers) will: Be randomized to receive either: Two 25 mg macrodoses of psilocybin separated by 1 week. Two placebo doses separated by 1 week. Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments. Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment. Receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the [18F]T807 radiotracer. Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment. Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.
Phase 2
Waitlist Available
Centre for Addiction and Mental HealthPhilip Gerretsen, MD, PhD
10 Psilocybin Clinical Trials Near Me

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: August 30th, 2023